In B-ALL, the age of onset and the prognosis differ according to the fusion partner: with the EP300/ZNF384 fusion, the median age of onset is 11 years and outcomes are excellent, whereas with the TCF3/ZNF384 fusion, the median age of onset is 5 years and there are occasional late relapses [78,80]. The gene discussed is EP300; the disease is acute lymphoblastic leukemia.